Coronary drug-eluting stent development: Issues in trial design - 21/08/11
Doi : 10.1016/j.ahj.2004.09.001
Neal I. Muni, MD, MSPH a, c, ⁎ 
, Robert M. Califf, MD b, Jonette R. Foy, PhD a, Ashley B. Boam, MS a, Bram D. Zuckerman, MD a, Richard E. Kuntz, MD, MS d
, Robert M. Califf, MD b, Jonette R. Foy, PhD a, Ashley B. Boam, MS a, Bram D. Zuckerman, MD a, Richard E. Kuntz, MD, MS d a Center for Devices and Radiological Health, U.S. Food and Drug Administration, Rockville, Md
b Department of Cardiology, Duke University Medical Center, Durham, NC
c Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass
d Department of Clinical Biometrics, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass
Reprint requests: Neal I. Muni, MD, MSPH, Medical Officer, Center for Devices and Radiological Health, US Food and Drug Administration, HFZ-450, 9200 Corporate Boulevard, Rockville, MD 20850.
Mappa
| This manuscript represents the professional opinion of the authors and is not an official document, agency, guidance, or policy of the US Government, the Department of Health and Human Services, or the Food and Drug Administration, nor should any official endorsement be inferred. |
© 2005
Pubblicato da Elsevier Masson SAS.
Vol 149 - N° 3
P. 415-433 - marzo 2005 Ritorno al numero
Articolo precedente
- Primary stenting of occluded native coronary arteries II—Rationale and design of the PRISON II study: A randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of chronic total coronary occlusions
- Braim M. Rahel, Gert J. Laarman, Maarten J. Suttorp, on behalf of the PRISON II study investigators
- Conducting economic evaluations alongside multinational clinical trials: Toward a research consensus
- Shelby D. Reed, Kevin J. Anstrom, Ameet Bakhai, Andrew H. Briggs, Robert M. Califf, David J. Cohen, Michael F. Drummond, Henry A. Glick, Ari Gnanasakthy, Mark A. Hlatky, Bernie J. O'Brien, Frank M. Torti, Anastasios A. Tsiatis, Andrew R. Willan, Daniel B. Mark, Kevin A. Schulman
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?